Content uploaded by Eric Wooltorton
Author content
All content in this area was uploaded by Eric Wooltorton on Oct 27, 2016
Content may be subject to copyright.
PRACTICE
CMAJ • AUG. 30, 2005; 173 (5) 485
© 2005 CMA Media Inc. or its licensors
Reason for posting:
Mifepristone
is used with misoprostol to termi-
nate early pregnancies and has
been taken by more than 460 000
women. The US Food and Drug
Administration (FDA) recently
advised of 4 women in the
United States who died of sepsis
after taking the drugs for medical
abortion. Two of the women had
Clostridium sordellii-related sepsis
(www.fda.gov/cder/drug/advisory
/mifeprex.htm). A Canadian wo-
man died in 2001 of C. sordellii-
related septic shock after taking
the drugs in a clinical trial.1
The drugs:
Mifepristone is a
progesterone receptor antagonist
and abortifacient, but was origi-
nally investigated for its antiglu-
cocorticoid effects as a potential
treatment for Cushing’s syn-
drome. Widely used in Europe
and the United States, it is not li-
censed for use in Canada. Ac-
cording to the FDA-approved
protocol, 600 mg of mifepristone
is taken orally within 49 days af-
ter the start of a woman’s last
menstrual period. Two days later
400 µg of the prostaglandin
misoprostol is taken orally to
soften the cervix and induce uter-
ine contractions if the pregnancy
has not already ended. Ten days
later the woman is followed up
clinically, often with ultrasonog-
raphy, to confirm termination of
her pregnancy. Complete med-
ical abortion occurs in about 92%
of women taking the regimen,
but 5%–8% require a surgical
procedure because of incomplete
abortion, excessive bleeding or
continuing pregnancy. Common
adverse effects of the regimen in-
clude abdominal cramping and
vaginal bleeding, headache, nau-
sea and vomiting, and diarrhea.
Rare but fatal cases of ruptured
ectopic pregnancy have occurred.
Mifepristone is metabolized in
the liver by CYP3A4.
The 4 FDA-reported deaths
occurred between 2003 and 2005
in California and involved women
who had taken the misoprostol
(800 µg) intravaginally. The in-
fective agent was not identified in
2 of the cases. The patients with
C. sordellii infection apparently
had similar presentations (Box 1).
C. sordellii is a gram-positive
anaerobe found ubiquitously in
soil and as part of the human in-
testinal flora. Ten percent of
women’s vaginas are colonized.
Infections are rare but have been
reported in patients of all ages
with both intact and compro-
mised immune systems. Death is
common, and the infections of-
ten occur after transcutaneous,
perineal or gastrointestinal pro-
cedures.2The organism produces
an endotoxin and can produce 2
potent exotoxins. C. sordellii sep-
sis in mifepristone users may oc-
cur through effects on cortisol or
cytokine responses.3
What to do:
Women should be
warned of this rare but poten-
tially fatal adverse effect. They
should seek immediate attention
if they have fever, severe abdom-
inal pain, very heavy bleeding,
syncope or general malaise.
However, clinicians must be
aware that all of the deaths from
C. sordellii sepsis reported here
involved symptoms listed in
Box 1. Prophylactic antibiotic
therapy is not recommended for
all women undergoing medical
abortion; however, for those with
suspected sepsis, complete blood
counts and necessary cultures
should be obtained and aggres-
sive, empirical treatment with
antibiotics started that includes
coverage against C. sordelli.
Sally Murray
Editorial Fellow
Eric Wooltorton
Associate Editor
CMAJ
References
1. Sinave C, Le Templier G, Bluin D,
Leville F, Deland E. Toxic shock syn-
drome due to Clostridium sordellii: a
dramatic postpartum and postabortion
disease. Clin Infect Dis 2002;35:1441-3.
2. Abdulla A, Yee L. The clinical spec-
trum of Clostridium sordellii bacteraemia:
two case reports and a review of the lit-
erature. J Clin Pathol 2000;53:709-12.
3. Miech RP. Pathophysiology of mife-
pristone-induced septic shock due to
Clostridium sordellii. Ann Pharmacother
2005 Jul 26 [Epub ahead of print].
DOI 10.1345/aph.1G189.
Septic shock after medical abortions with mifepristone
(Mifeprex, RU 486) and misoprostol
HEALTH AND DRUG ALERTS
DOI:10.1503/cmaj.050980
Canadian Adverse Reaction Newsletter
Bulletin canadien des effets indésirables
To receive the Newsletter and health product Advisories free by email,
join Health Canada’s MedEffect mailing list.
Go to www.hc-sc.gc.ca/dhp-mps/medeff/subscribe-abonnement/index_e.html.
Inscrivez-vous à la liste MedEffet de Santé Canada pour recevoir gratuitement par
courriel le Bulletin et les Avis au sujet des produits de santé. Rendez-vous à l’adresse
www.hc-sc.gc.ca/dhp-mps/medeff/subscribe-abonnement/index_f.html.
Report adverse reactions toll free to Health Canada
Signaler sans frais des effets indésirables à Santé Canada
Tel./Tél. : 866 234-2345 • Fax/Téléc. : 866 678-6789
Box 1: Characteristics of
Clostridium
sordellii
septic shock after medical abortion
with mifepristone and misoprostol
•Little or no fever
•Variable nausea, vomiting, weakness and
abdominal pain (often little)
•Rapid deterioration (within hours or days)
•Tachycardia and refractory hypotension
•Multiple effusions
•Elevated hematocrit
•Elevated leukocyte count, neutrophilia
Early release
All Health and Drug Alerts
are posted online ahead of
print and are available at
www.cmaj.ca. This article
was posted on Aug. 10,
2005.